The CD47 Signal That Oncology Trial Designers Are Misreading
Evorpacept's Phase 2 data in HER2+ gastric cancer reveals a CD47 biomarker selection gap that could reshape how oncology...
Phase III Trial Amendments Average 3.5, Up From 2.3 a Decade Ago
Phase III trial amendments now average 3.5 per study, up from 2.3 a decade ago, with each costing a...
Tekton Research Hires Three VPs to Support Multi-Site Trial Growth
Tekton Research hires three VPs to strengthen multi-site trial growth, addressing sponsor demands for better coordination and participant retention...
XtalPi Files IND for KQTD-126, Gut-Restricted TRK Inhibitor for Chronic Intestinal Pain
XtalPi's KQTD-126, a gut-restricted TRK inhibitor, targets chronic intestinal pain in IBS and IBD with a tissue-to-blood ratio above...
Acadia Reports Phase 2 Results for Remlifanserin in Alzheimer’s Disease Psychosis
Acadia reports Phase 2 results for remlifanserin in Alzheimer's disease psychosis, with Phase 3 trials already underway and FDA...
Kyverna Reports One-Year miv-cel Data in Stiff Person Syndrome, gMG
Kyverna reports one-year miv-cel data in stiff person syndrome showing durable clinical responses and favorable safety, supporting potential registrational...
Sefaxersen Meets Primary Endpoint in Phase 3 IgA Nephropathy Trial
Sefaxersen meets primary endpoint in Phase 3 IgA Nephropathy trial, showing statistically significant proteinuria reduction in adults with primary...
Teclistamab plus daratumumab shows 18-point survival gain at 3 years in multiple myeloma
Teclistamab plus daratumumab demonstrated an 18-percentage-point survival advantage at 3 years in relapsed multiple myeloma patients with 1–3 prior...
aTyr Pharma Reaches FDA Protocol Agreement for Efzofitimod Phase 3 Trial
aTyr Pharma reaches FDA protocol agreement for efzofitimod Phase 3 trial in pulmonary sarcoidosis, paving the way for global...
Scaling Clinical AI to One Million Patients Taught Us Things No Pilot Study Could
A Nature Medicine analysis of 1M+ patient AI deployments across three healthcare systems reveals the infrastructure gaps sponsors must...